Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 126 от 222

Набира участници Фаза 2

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathic Pain

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)

Начало: 18.10.2024 Край: 30.05.2026 Възраст: 18–80 г.

Canada, France, Germany +3 Vertex Pharmaceuticals Incorporated NCT06619860

Набира участници Фаза 3

Nebulized Ketamine for the Treatment of Major Depressive Disorder

Severe Depression Moderate Depression Ketamine Midazolam +13

This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

Начало: 16.10.2024 Край: 30.09.2027 Възраст: 18–88 г.

United States Theresa Jacob, PhD, MPH NCT06752759

Набира участници Фаза 1

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Asthma

The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.

Начало: 16.10.2024 Край: 07.06.2027 Възраст: 18–65 г. Лечение

Australia, Belgium, Canada +2 Amgen NCT06637371

Набира участници Фаза 2/3

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

Начало: 16.10.2024 Край: 25.12.2026 Възраст: 12–17 г.

Italy, Poland, South Korea +2 UCB Biopharma SRL NCT06055959

Набира участници Фаза 1

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Pancreatic Ductal Adenocarcinoma Non-small Cell Lung Cancer HR+/HER2- Ductal and Lobular Breast Cancer Triple Negative Breast Cancer +1

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Начало: 15.10.2024 Край: 16.01.2031 Възраст: 18–100 г.

Belgium, Canada, France +7 Novartis Pharmaceuticals NCT06562192

Набира участници

Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)

Liver Neoplasms Primary Liver Cancer Secondary Liver Cancer Tumor Liver +1

The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.

Начало: 14.10.2024 Край: 01.11.2031 Възраст: от 22 г.

United States HistoSonics, Inc. NCT06486454

Набира участници

Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11)

Atrial Fibrillation

EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial). The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity burden (CHA2DS2-VASc ≥4) reduces cardiovascular events (stroke, cardiovascular death, or heart failure events) compared to usual care.

Начало: 14.10.2024 Край: 01.05.2030 Възраст: от 18 г. Превенция

Australia, Canada, Germany +4 Atrial Fibrillation Network NCT06324188

Набира участници Фаза 1

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

Advanced Solid Tumor Metastatic Breast Cancer Metastatic Ovarian Cancer Metastatic Endometrial Cancer +2

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

Начало: 14.10.2024 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia EtiraRx Australia Pty Ltd NCT06533332

Набира участници Фаза 2

Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

Neuroendocrine Tumors

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not. The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.

Начало: 14.10.2024 Край: 01.06.2028 Възраст: от 18 г. Лечение

Australia, Canada Australasian Gastro-Intestinal Trials Group NCT06345079

Набира участници Фаза 2

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Solid Tumours

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into 13 groups based on the type of advanced cancer and the type of HER2 alterations they have. All participants take one dose of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.

Начало: 11.10.2024 Край: 29.12.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +13 Boehringer Ingelheim NCT06581432

Набира участници Фаза 1

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

Advanced Solid Tumor

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894, and in combination with standard of care therapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.

Начало: 11.10.2024 Край: 01.01.2029 Възраст: от 18 г. Лечение

Australia, China, Denmark +4 BeOne Medicines NCT06589596

Набира участници

Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial

Ischemic Stroke, Acute

Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \

Начало: 11.10.2024 Край: 01.05.2026 Възраст: от 18 г. Лечение

Australia, Canada The George Institute NCT06352619

Набира участници Фаза 2

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis Ulcerative Colitis Chronic

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).

Начало: 10.10.2024 Край: 01.09.2028 Възраст: 18–75 г.

Argentina, Belgium, Canada +18 Eli Lilly and Company NCT06598943

Набира участници Фаза 1/2

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Ulcerative Colitis (UC)

Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

Начало: 10.10.2024 Край: 01.01.2029 Възраст: 18–75 г. Лечение

Australia, Bulgaria, Canada +8 Xencor, Inc. NCT06619990

Набира участници Фаза 2

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

Episodic Migraine Chronic Migraine

A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics. This study aims to determine: * The safety and efficacy of injecting IPN10200 directly into the muscles of the head and neck to prevent EM and CM, * The right amount (dose) of IPN10200 to inject at each point, * The total amount (dose) of IPN10200 that provides the best balance between safety and efficacy preventing migraines. Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.

Начало: 10.10.2024 Край: 15.06.2027 Възраст: 18–80 г. Лечение

Australia, Brazil, Canada +11 Ipsen NCT06625060

Набира участници

Aerobic Exercise Versus Digital Cognitive Behavioral Therapy for Insomnia

Insomnia Chronic

The purpose of this study is to compare the effects of aerobic exercise versus digital CBT-I in university students with insomnia complaints. This is a clinical trial. Participants will be randomized into two groups: aerobic exercise (n=25) and digital CBT-I (n=25). The severity of insomnia, sleep quality, pre-sleep cognitive and somatic arousal, and participants' complaints of depression, anxiety, and stress will be assessed using self-administered questionnaires. Based on previous studies describing the effects of physical exercise on chronic insomnia, the hypothesis of this study is that aerobic exercise promotes similar results compared to digital CBT-I in insomnia severity and sleep quality, in addition to improving the complaints of depression, anxiety and stress of the participants.

Начало: 10.10.2024 Край: 30.12.2027 Възраст: от 18 г.

Brazil Universidade Federal de Goias NCT06636006

Набира участници Фаза 1/2

Study of LM-299 in Subjects Advanced Malignant Tumors

Malignant Tumors

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours.. For Phase II Dose Expansion Stage, to assess the antitumor activity of LM-299 in patients with various advanced solid tumors.

Начало: 09.10.2024 Край: 01.07.2027 Възраст: 18–80 г. Лечение

Australia, China LaNova Medicines Limited NCT06650566

Набира участници Фаза 1

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Solid Tumor, Adult Bladder Cancer Urothelial Carcinoma Triple-negative Breast Cancer +5

This is an open-label, uncontrolled, multi-center, phase 1a MNPR-101-PCTA-177Lu dose-escalation study in patients with solid tumor cancers. Patients must have participated in the imaging study MNPR-101-D001 (actively recruiting, diagnostic study of MNPR-101-DFO\*-89Zr). * TITE-BOIN will be used to objectively determine dose increase, no dose change, or dose decrease for each group of two patients. * The treatment period consists of two 12-week cycles. Patients will receive three equal fractions of MNPR-101-PCTA-177Lu with radioactivity ranging from 480-2240 MBq on each of Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (12 weeks after Cycle 1 Day 1). * Patients will be followed for 12 weeks after their last dose of MNPR-101-PCTA-177Lu. * Patients will be imaged at specific timepoints during the study.

Начало: 08.10.2024 Край: 01.01.2027 Възраст: от 18 г. Лечение

Australia Monopar Therapeutics NCT06617169

Набира участници

Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer

Rectal Carcinoma

This study evaluates whether images taken using a photon counting detector CT scanner (PCD-CT) can determine the growth of rectal cancer as well as, or better than, MRI for the management of patients with rectal cancer.

Начало: 07.10.2024 Край: 31.12.2026 Възраст: 18–99 г.

United States Mayo Clinic NCT06965166

Набира участници Фаза 1

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Extensive Stage Small Cell Lung Cancer

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Начало: 07.10.2024 Край: 27.03.2030 Възраст: от 18 г. Фундаментална наука

Australia, Belgium, China +7 Amgen NCT06598306

1 … 124 125 126 127 128 … 222